What is the HPV vaccine recommendation and rationale for vaccination timing?

• A. Vaccinate at ages 21–60; not supported by guidelines.
• B. Vaccinate at ages 11–12; catch-up through 26; shared decision-making for 27–45; prevents HPV infections and cervical cancer by targeting high-risk types.
• C. Vaccinate only after first pregnancy.
• D. Vaccinate only for high-risk groups.

Answer: (B)

Vaccination timing is guided by maximizing protection before exposure to HPV, since the vaccine works best when given before people encounter the virus. That’s why routine vaccination is recommended in early adolescence, around 11–12 years old, with a catch-up window through age 26 for those who weren’t vaccinated earlier. For adults aged 27–45, the decision to vaccinate should be made through shared decision-making, weighing the person’s risk of new HPV exposure and the potential benefit they might gain.

The vaccine protects against the high‑risk HPV types that cause the vast majority of cervical cancers and other HPV-related cancers by preventing new HPV infections rather than treating existing infections. Early vaccination also tends to produce a stronger and longer-lasting immune response.

So the best approach is to vaccinate at 11–12 with catch-up through 26, and to discuss vaccination with adults 27–45 on an individual basis, because this strategy offers the greatest chance to prevent HPV‑related disease across the population.